Versant Capital Management’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $51.5K | Sell |
95
-87
| -48% | -$45K | ﹤0.01% | 1384 |
|
|
2026
Q2 | $98.6K | Buy |
182
+88
| +94% | +$49.6K | 0.01% | 947 |
|
|
2026
Q1 | $55.7K | Buy |
94
+57
| +154% | +$28.4K | 0.01% | 1165 |
|
|
2025
Q4 | $18K | Buy |
37
+6
| +19% | +$2.79K | ﹤0.01% | 1707 |
|
|
2025
Q3 | $13K | Hold |
31
| – | – | ﹤0.01% | 1815 |
|
|
2025
Q2 | $8.91K | Sell |
31
-22
| -42% | -$6.58K | ﹤0.01% | 1939 |
|
|
2025
Q1 | $16.3K | Buy |
53
+25
| +89% | +$8.57K | ﹤0.01% | 1455 |
|
|
2024
Q4 | $9.9K | Buy |
28
+19
| +211% | +$6.98K | ﹤0.01% | 1404 |
|
|
2024
Q3 | $3.22K | Hold |
9
| – | – | ﹤0.01% | 1422 |
|
|
2024
Q2 | $2.87K | Hold |
9
| – | – | ﹤0.01% | 1403 |
|
|
2024
Q1 | $2.07K | Hold |
9
| – | – | ﹤0.01% | 1337 |
|
|
2023
Q4 | $1.98K | Hold |
9
| – | – | ﹤0.01% | 1287 |
|
|
2023
Q3 | $2.03K | Hold |
9
| – | – | ﹤0.01% | 1308 |
|
|
2023
Q2 | $1.99K | Buy |
9
+5
| +125% | +$1.11K | ﹤0.01% | 1374 |
|
|
2023
Q1 | $876 | Hold |
4
| – | – | ﹤0.01% | 1476 |
|
|
2022
Q4 | $1.11K | Hold |
4
| – | – | ﹤0.01% | 1274 |
|
|
2022
Q3 | $1K | Hold |
4
| – | – | ﹤0.01% | 1364 |
|
|
2022
Q2 | $1K | Hold |
4
| – | – | ﹤0.01% | 1371 |
|
|
2022
Q1 | $1K | Buy |
4
+2
| +100% | +$381 | ﹤0.01% | 1388 |
|
|
2021
Q4 | $0 | Hold |
2
| – | – | ﹤0.01% | 1597 |
|
|
2021
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 1607 |
|
|
2021
Q2 | $0 | Hold |
2
| – | – | ﹤0.01% | 1603 |
|
|
2021
Q1 | $0 | Hold |
2
| – | – | ﹤0.01% | 1610 |
|
|
2020
Q4 | $0 | Hold |
2
| – | – | ﹤0.01% | 1540 |
|
|
2020
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 1516 |
|
|
2020
Q2 | $0 | Hold |
2
| – | – | ﹤0.01% | 1563 |
|
|
2020
Q1 | $0 | Hold |
2
| – | – | ﹤0.01% | 1689 |
|
|
2019
Q4 | $0 | Sell |
2
-8
| -80% | -$704 | ﹤0.01% | 1593 |
|
|
2019
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 1598 |
|
|
2019
Q2 | $0 | Hold |
10
| – | – | ﹤0.01% | 1710 |
|
|
2019
Q1 | $1K | Sell |
10
-3
| -23% | -$350 | ﹤0.01% | 1493 |
|
|
2018
Q4 | $1K | Hold |
13
| – | – | ﹤0.01% | 1406 |
|
|
2018
Q3 | $1K | Hold |
13
| – | – | ﹤0.01% | 1452 |
|
|
2018
Q2 | $1K | Hold |
13
| – | – | ﹤0.01% | 1434 |
|
|
2018
Q1 | $1K | Hold |
13
| – | – | ﹤0.01% | 1417 |
|
|
2017
Q4 | $1K | Hold |
13
| – | – | ﹤0.01% | 1466 |
|
|
2017
Q3 | $1K | Hold |
13
| – | – | ﹤0.01% | 1379 |
|
|
2017
Q2 | $1K | Hold |
13
| – | – | ﹤0.01% | 1380 |
|
|
2017
Q1 | $1K | Hold |
13
| – | – | ﹤0.01% | 1377 |
|
|
2016
Q4 | $1K | Sell |
13
-5
| -28% | -$638 | ﹤0.01% | 1331 |
|
|
2016
Q3 | $2K | Sell |
18
-4
| -18% | -$481 | ﹤0.01% | 1216 |
|
|
2016
Q2 | $2K | Buy |
22
+5
| +29% | +$558 | ﹤0.01% | 1180 |
|
|
2016
Q1 | $1K | Hold |
17
| – | – | ﹤0.01% | 1289 |
|
|
2015
Q4 | $2K | Buy |
+17
| New | +$2.48K | ﹤0.01% | 1168 |
|
Other funds holding UTHR
Versant Capital Management's UTHR Position: Q3 2026 in Review
Versant Capital Management reduced its United Therapeutics (UTHR) stake by 48% in Q3 2026, selling an estimated $45K and leaving 95 shares worth $51.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1384.
Versant Capital Management first reported a position in UTHR in Q4 2015 and has held it in 44 quarters since. The position peaked at $98.6K in Q2 2026. 673 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.
- Versant Capital Management held 95 shares of United Therapeutics worth $51.5K as of Q3 2026.
- Versant Capital Management sold 87 United Therapeutics shares in Q3 2026, an estimated $45K.
- United Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1384 holding.
- Versant Capital Management first reported a position in United Therapeutics in Q4 2015 and has held it in 44 quarters since.
- Versant Capital Management's United Therapeutics position peaked at $98.6K in Q2 2026.
- 673 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.
Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.